Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

1.

Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia.

Radvansky LJ, Pace MB, Siddiqui A.

Am J Health Syst Pharm. 2013 Jun 15;70(12):1025-32. doi: 10.2146/ajhp120467. Review.

PMID:
23719879
[PubMed - indexed for MEDLINE]
2.

Treatment of head and neck cancers: issues for clinical pharmacists.

Scarpace SL, Brodzik FA, Mehdi S, Belgam R.

Pharmacotherapy. 2009 May;29(5):578-92. doi: 10.1592/phco.29.5.578. Review.

PMID:
19397465
[PubMed - indexed for MEDLINE]
3.

Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.

Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):739-47.

PMID:
11849797
[PubMed - indexed for MEDLINE]
4.

The role of saliva in oral health: strategies for prevention and management of xerostomia.

Brosky ME.

J Support Oncol. 2007 May;5(5):215-25. Review.

PMID:
17564151
[PubMed - indexed for MEDLINE]
5.

Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.

Büntzel J, Glatzel M, Kuttner K, Weinaug R, Fröhlich D.

Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):4-13.

PMID:
11917277
[PubMed - indexed for MEDLINE]
6.

Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.

de Castro G Jr, Federico MH.

Curr Opin Oncol. 2006 May;18(3):266-70. Review.

PMID:
16552239
[PubMed - indexed for MEDLINE]
7.

How to reduce radiation-related toxicity in patients with cancer of the head and neck.

Garden AS, Lewin JS, Chambers MS.

Curr Oncol Rep. 2006 Mar;8(2):140-5. Review.

PMID:
16507224
[PubMed - indexed for MEDLINE]
8.

Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.

Law A, Kennedy T, Pellitteri P, Wood C, Christie D, Yumen O.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1361-8. Epub 2007 Sep 14.

PMID:
17869022
[PubMed - indexed for MEDLINE]
9.

Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?

Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K, Richter E, Feyerabend T.

Strahlenther Onkol. 2003 Jun;179(6):385-9.

PMID:
12789464
[PubMed - indexed for MEDLINE]
10.
11.

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.

Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R.

J Clin Oncol. 2000 Oct 1;18(19):3339-45. Erratum in: J Clin Oncol 2000 Dec 15;18(24):4110-1.

PMID:
11013273
[PubMed - indexed for MEDLINE]
Free Article
12.

Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.

Sasse AD, Clark LG, Sasse EC, Clark OA.

Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):784-91. Epub 2005 Sep 29. Review.

PMID:
16198504
[PubMed - indexed for MEDLINE]
13.

Management of salivary hypofunction during and after radiotherapy.

Shiboski CH, Hodgson TA, Ship JA, Schiødt M.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103 Suppl:S66.e1-19. Review.

PMID:
17379158
[PubMed - indexed for MEDLINE]
14.

Emerging approaches for prophylaxis and management of oropharyngeal mucositis in cancer therapy.

Epstein JB, Klasser GD.

Expert Opin Emerg Drugs. 2006 May;11(2):353-73. Review.

PMID:
16634706
[PubMed - indexed for MEDLINE]
15.

Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.

Ozsahin M, Betz M, Matzinger O, Bron L, Luthi F, Pasche P, Azria D, Mirimanoff RO, Zouhair A.

Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):141-5.

PMID:
16490870
[PubMed - indexed for MEDLINE]
16.

Amifostine in the management of radiation-induced and chemo-induced mucositis.

Bensadoun RJ, Schubert MM, Lalla RV, Keefe D.

Support Care Cancer. 2006 Jun;14(6):566-72. Epub 2006 Apr 4. Review.

PMID:
16586122
[PubMed - indexed for MEDLINE]
17.

Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.

Thorstad WL, Chao KS, Haughey B.

Semin Oncol. 2004 Dec;31(6 Suppl 18):8-12.

PMID:
15726516
[PubMed - indexed for MEDLINE]
19.

Systematic review of amifostine for the management of oral mucositis in cancer patients.

Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias VE, Niscola P, Riesenbeck D, Stokman M, Tissing W, Yeoh E, Elad S, Lalla RV; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2013 Jan;21(1):357-64. doi: 10.1007/s00520-012-1613-6. Epub 2012 Oct 3. Review.

PMID:
23052919
[PubMed - indexed for MEDLINE]
20.

Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.

Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME.

Cancer. 2009 Mar 15;115(6):1286-99. doi: 10.1002/cncr.24120.

PMID:
19170238
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk